Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. https://doi.org/10.1016/j.jhep.2020.03.039
Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1991. https://doi.org/10.1053/j.gastro.2019.11.312
CAS Article PubMed Google Scholar
Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138-2147.e2110. https://doi.org/10.1016/j.cgh.2020.12.022
Lee H, Lee HW, Kim SU, Chang Kim H. Metabolic dysfunction-associated fatty liver disease increases colon cancer risk: a nationwide cohort study. Clin Transl Gastroenterol 2022;13(1):e00435. https://doi.org/10.14309/ctg.0000000000000435
Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–1128. https://doi.org/10.1111/hepr.13685
CAS Article PubMed Google Scholar
Seong SC, Kim YY, Park SK, Khang YH, Kim HC, Park JH, et al. Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. BMJ Open. 2017;7(9): e016640. https://doi.org/10.1136/bmjopen-2017-016640
Article PubMed Central PubMed Google Scholar
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004
Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, et al. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS ONE. 2014;9(9): e107584. https://doi.org/10.1371/journal.pone.0107584
CAS Article PubMed Central PubMed Google Scholar
Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68(2):305–315. https://doi.org/10.1016/j.jhep.2017.11.013
CAS Article PubMed Google Scholar
Lee H, Yano Y, Cho SMJ, Park JH, Park S, Lloyd-Jones DM, et al. Cardiovascular risk of isolated systolic or diastolic hypertension in young adults. Circulation. 2020;141(22):1778–1786. https://doi.org/10.1161/CIRCULATIONAHA.119.044838
Seo HJ, Oh IH, Yoon SJ. A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev. 2012;13(12):6163–6168. https://doi.org/10.7314/apjcp.2012.13.12.6163
Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A, et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol. 2007;22(6):794–800. https://doi.org/10.1111/j.1440-1746.2007.04952.x
Bhatnagar A. Environmental determinants of cardiovascular disease. Circ Res. 2017;121(2):162–180. https://doi.org/10.1161/CIRCRESAHA.117.306458
CAS Article PubMed Central PubMed Google Scholar
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600. https://doi.org/10.1016/j.jhep.2016.05.013
Fox CS, Coady S, Sorlie PD, D’Agostino RB Sr, Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115(12):1544–1550. https://doi.org/10.1161/circulationaha.106.658948
King RJ, Grant PJ. Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. Herz. 2016;41(3):184–192. https://doi.org/10.1007/s00059-016-4414-8
CAS Article PubMed Google Scholar
Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022–1032. https://doi.org/10.1007/s00535-021-01828-6
CAS Article PubMed Central PubMed Google Scholar
Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes. 2019;37(1):65–72. https://doi.org/10.2337/cd18-0026
Article PubMed Central PubMed Google Scholar
Yoshitaka H, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study. Medicine (Baltimore). 2017;96(18): e6712. https://doi.org/10.1097/md.0000000000006712
Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H, et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12(5):491–502. https://doi.org/10.1080/17474124.2018.1460202
CAS Article PubMed Google Scholar
Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study. Clin Gastroenterol Hepatol. 2022;20(6):1374-1381.e1376. https://doi.org/10.1016/j.cgh.2021.07.016
CAS Article PubMed Google Scholar
Han E, Lee YH, Kim YD, Kim BK, Park JY, Kim DY, et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am J Gastroenterol 2020;115(4):584–595. https://doi.org/10.14309/ajg.0000000000000572
Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Inada K, Kirino S, et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol. 2021;36(10):2960–2966. https://doi.org/10.1111/jgh.15589
CAS Article PubMed Google Scholar
Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2021. https://doi.org/10.5009/gnl210084
Article PubMed Central PubMed Google Scholar
Han E, Lee YH, Lee BW, Kang ES, Lee IK, Cha BS. Anatomic fat depots and cardiovascular risk: a focus on the leg fat using nationwide surveys (KNHANES 2008–2011). Cardiovasc Diabetol. 2017;16(1):54. https://doi.org/10.1186/s12933-017-0536-4
CAS Article PubMed Central PubMed Google Scholar
Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol. 2009;20(2):353–357
CAS Article PubMed Google Scholar
Sohn W, Kwon HJ, Chang Y, Ryu S, Cho YK. Liver fibrosis in Asians with metabolic dysfunction-associated fatty liver disease. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.06.042
Chen X, Chen S, Pang J, Tang Y, Ling W. Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality? J Hepatol. 2021;75(4):987–989. https://doi.org/10.1016/j.jhep.2021.06.013
Lee JI, Lee HW, Lee KS, Lee HS, Park JY. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case–control study. Am J Gastroenterol 2021;116(1):116–124. https://doi.org/10.14309/ajg.0000000000000845
留言 (0)